Short Interest in Curis, Inc. (NASDAQ:CRIS) Grows By 10.9%

Curis, Inc. (NASDAQ:CRIS) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 42,700 shares, an increase of 10.9% from the June 30th total of 38,500 shares. Based on an average daily volume of 28,000 shares, the short-interest ratio is presently 1.5 days. Approximately 0.7% of the shares of the stock are short sold.

Curis Stock Performance

NASDAQ:CRIS traded down $0.33 during trading hours on Wednesday, reaching $5.48. The stock had a trading volume of 37,560 shares, compared to its average volume of 32,446. The stock has a market capitalization of $32.28 million, a PE ratio of -0.64 and a beta of 3.35. Curis has a 52 week low of $3.80 and a 52 week high of $17.49. The company has a 50 day moving average price of $7.83 and a two-hundred day moving average price of $10.63.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.94) by ($0.11). Curis had a negative return on equity of 224.75% and a negative net margin of 486.45%. The business had revenue of $2.09 million during the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the prior year, the firm posted ($2.40) EPS. Equities research analysts predict that Curis will post -5.39 EPS for the current year.

Institutional Trading of Curis

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the last quarter. CM Management LLC boosted its holdings in shares of Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares during the period. Focused Wealth Management Inc increased its position in shares of Curis by 79.2% during the 1st quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 14,656 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in Curis during the 1st quarter valued at $219,000. Finally, a16z Perennial Management L.P. bought a new stake in Curis in the fourth quarter worth $85,000. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on CRIS. Truist Financial restated a “buy” rating and issued a $26.00 price target on shares of Curis in a research note on Wednesday, May 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Curis in a research report on Wednesday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Curis in a report on Wednesday, May 15th.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.